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OBJECTIVES The purpose of this study was to prospectively analyze the performance and safety of a new
programmable, fully automatic external cardioverter-defibrillator (AECD) in a European
multicenter trial.
BACKGROUND Although, the response time to cardiac arrest (CA) is a major determinant of mortality and
morbidity, in-hospital strategies have not significantly changed during the last 30 years.
METHODS Patients (n  117) at risk of CA in monitored wards (n  51) and patients undergoing
electrophysiologic testing or implantable cardioverter-defibrillator (ICD) implantation (n 
66) were enrolled. The accuracy of the automatic response of the device to any change of
rhythm (lasting 1 s and 4 beats) was confirmed by reviewing the simultaneously recorded
Holter data and the programmed parameters.
RESULTS During 1,240 h, 1,988 episodes of rhythm changes were documented. A total of 115 episodes
lasted 10 s or needed treatment (pacing, n  32; ICD, n  51; AECD, n  35) for
termination. The device detected ventricular tachyarrhythmias with a sensitivity of 100% and
specificity of 97.6% (true negatives, n  1,454; true positives, n  499; false positives, n 
35; false negatives, n  0). The false positives were all caused by T-wave oversensing during
ventricular pacing. There were no complications or adverse events. The mean response time
was 14.4 s for those episodes needing a full charge of the capacitor.
CONCLUSIONS This new AECD is safe and effective in detecting, monitoring, and treating spontaneous
arrhythmias. This fully automatic device shortens the response time to treatment, and it is
likely that it will significantly improve the outcome of patients with in-hospital CA. (J Am
Coll Cardiol 2003;41:627–32) © 2003 by the American College of Cardiology Foundation
Time to defibrillation is the single most important deter-
minant of survival in cardiac arrest (CA) (1–15) as a result
of several factors: 1) the most frequent rhythm at the start of
resuscitation maneuvers is ventricular fibrillation (VF); 2)
the most effective treatment for VF or ventricular tachycar-
dia (VT) is usually electrical defibrillation; 3) the probability
of successful defibrillation diminishes rapidly over time
(4,10,14); and 4) VF tends to evolve to asystole within a few
minutes (1–3,5,6,10,11,16). Survival rates after VF decrease
approximately 7% to 10% with every minute that defibril-
lation is delayed (1–3,5,6). Furthermore, the cerebral cortex
is irreversibly damaged if circulation is not quickly resumed
(1,5,8,9,13,16,17).
Although ample evidence exists supporting the need for
rapid defibrillation, and important advances in out-of-
hospital CA treatment have been achieved (e.g., out-of-
hospital CA quick response programs) (1–3,6–12,14,18),
in-hospital CA is still a major problem without major
advances (e.g., changing strategies) during the last 30 years,
which has led to significant mortality and morbidity
(8,13,19,20). Therefore, the aim of the present study was to
prospectively analyze the performance and safety of a full
in-hospital automatic external cardioverter-defibrillator
(AECD).
PATIENTS AND METHODS
Patients. Patients (n 117; 18 years of age or older) at risk
of sustained VT or VF in the intensive care unit, coronary
care unit, or emergency room (n  51) and patients
undergoing electrophysiologic testing (because of docu-
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mented or suspected VT/VF) or implantation of implant-
able cardioverter-defibrillators (ICD) (n  66) were in-
cluded in this prospective, multicenter European study.
From the 117 patients, 2 patients were studied under both
invasive and noninvasive conditions. Thus, all patients
enrolled were in a monitored setting. Patients with previ-
ously implanted and activated cardioverter-defibrillators or
pacemakers were excluded. Atrial fibrillation was not con-
sidered as an exclusion criterion.
Methods. In addition to the standards of care of each
institution, patients underwent monitoring of their cardiac
rhythm by the new AECD (Powerheart, Cardiac Science
Inc., Irvine, California) using self-adhesive electrodes. Each
AECD provided an analog output electrocardiographic
(ECG) signal, which was recorded by conventional Holter
system for off-line review and confirmation of the patients’
rhythms.
The programmed detection rates of tachyarrhythmias,
therapy, as well as the duration and placement of leads (e.g.,
sternal-apex or anterior-posterior) for monitoring were at
the discretion of the treating physicians based on the
individual characteristics of patients. During ICD implan-
tations, the AECD was used as a “rescue” defibrillator.
Pacing is considered a contraindication for AECD use but
was used in the study for investigational purposes only.
Enrollment of participating clinical centers and patients did
comply with the requirements of the individual clinical
institutions (e.g., Ethical Committee), including informed
written consent of patients.
All adverse events or unanticipated adverse device events
relating to the rights, safety, or welfare of patients had to be
reported.
Device description. The AECD is designed to continu-
ously monitor, analyze, and classify the ECG rhythm of
patients. Upon detection of a ventricular tachyarrhythmia,
the AECD can provide treatment by automatically deliver-
ing cardioversion and/or defibrillation energy in seconds,
when needed (automatic mode). Should the arrhythmia
persist, the AECD can proceed with a subsequent delivery
of energy (up to 9 shocks per episode) after each additional
evaluation and charging period. The energy and delay of
each shock can be programmed. Shock delivery is noncom-
mitted such that if the rhythm spontaneously converts,
therapy will be automatically aborted.
The AECD can also operate in advisory mode, whereby
the device charges the capacitor when a ventricular tachy-
arrhythmia is detected and prompts the operator to press the
paired shock delivery buttons. When the device works in
advisory mode, it automatically discharges internally if a
shock has not been delivered within 1 min.
The AECD has a third mode of operation: the manual
mode. This allows the operator to select the energy, charge
the capacitor, and deliver the therapy when needed. The
manual mode was not evaluated in this study.
Tachyarrhythmias were detected primarily using a pro-
grammable rate criterion. Furthermore, for better discrim-
ination of supraventricular versus ventricular rhythms, a
modulation domain function, which combines frequency
and amplitude content of the signal (21), was available at
the physician’s discretion. Each time a ventricular tachyar-
rhythmia is detected, the device immediately and automat-
ically prints an ECG of the episode. Furthermore, episodes
lasting longer than 10 s are internally stored and may be
transferred to any conventional personal computer for doc-
umentation. A delay (10 to 600 s) between arrhythmia
recognition and shock delivery can be programmed by the
operator. This AECD has been approved by the Food and
Drug Administration as well as by the European Commu-
nity Administration.
Data analysis. Demographic, programmed parameters and
evaluation data (including ECG strips and Holter tapes)
were entered into a database for analysis. As the Holter
tapes were used to evaluate the patient outcomes, the Holter
recordings were classified into episodes. They were deter-
mined from the time a rhythm change (e.g., supraventricular
vs. ventricular) was established until the end of the rhythm
change or when therapy was delivered, whichever occurred
first. Only rhythms persisting more than 1 s and lasting
more than 4 beats were considered as an episode. Because
every change of rhythm constituted a new challenge for the
AECD, the response of the device to all episodes was
evaluated. Thus, each episode documented with the Holter
tapes was analyzed and classified as true positive, true
negative, false positive, or false negative on the basis of the
programmed parameters and the device response to the
tachyarrhythmia (review of stored data and all ECG strips).
Sensitivity was calculated as true positives divided by the
sum of true positives and false negatives. Specificity was
calculated as true negatives divided by the sum of true
negatives and false positives.
The response time was evaluated in those episodes
leading to a full charge of the capacitor. It was defined as the
sum of the arrhythmia recognition period and the charging
period. As mentioned in the previous text, the minimum
programmable arrhythmia-to-shock delay was 10 s. For
those episodes in which a prolonged arrhythmia-to-shock
delay had been programmed (e.g., 30 s), the response time
included only the recognition and charging time and was
considered 10 s if that sum had been shorter.
Continuous data are presented as mean  SD.
Abbreviations and Acronyms
AECD  automatic external cardioverter-defibrillator
CA  cardiac arrest
ECG  electrocardiograph/electrocardiographic
ICD  implantable cardioverter-defibrillator
VF  ventricular fibrillation
VT  ventricular tachycardia
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RESULTS
A total of 117 patients were included in the study: 51
patients (44%) in monitoring wards (emergency room,
intensive care unit, or coronary care unit) and 66 patients
(56%) during electrophysiologic studies or ICD implanta-
tions. From the overall cohort, two patients were studied
under both invasive and noninvasive conditions. The mean
age was 62  16 years; 25 patients were female (21.4%).
Cardiac diagnoses included coronary artery disease (n  72
[61.5%]), dilated cardiomyopathy (n  11 [9.4%]), hyper-
trophic cardiomyopathy (n  6 [5.1%]), valvular heart
disease (n 5 [4.3%]), and others (n 23 [19.7%]). Eleven
patients (9.4%) presented with persistent atrial fibrillation,
whereas 106 patients (90.6%) presented in sinus rhythm.
A total of 125 and 1,115 h of monitoring were performed
during invasive procedures and at the ward, respectively.
During the combined monitoring (1,240 h), a total of 1,988
episodes of change of rhythm occurred. A total of 115
episodes (5.8%; ventricular origin, n  84; spontaneous, n
 38) lasted 10 s or needed electrical treatment for
termination. During invasive procedures, a total of 34, 5,
and 16 episodes (10 s) of monomorphic or polymorphic
VT and VF were documented, respectively. In monitoring
wards, 10, 2, and 17 episodes of those arrhythmias occurred,
respectively.
The mean programmed ventricular arrhythmia detection
rate was 166  13 beats/min. There were no significant
differences of programmed parameters at the ward com-
pared with during invasive procedures. The modulation
domain function was used by the investigators in 74 patients
(63%) (ward, n  28; invasive procedures, n  46; mean
programmed rate 185  9 beats/min). According to the
programmed parameters, there were 1,454 true negatives,
499 true positives, 35 false positives, and no false negatives.
Thus, sensitivity was 100% and specificity was 97.6%
(97.3% for invasive procedures; 99.2% for monitoring at the
ward). False positives resulted from T-wave oversensing
during ventricular pacing in five patients (Fig. 1). Because
the device was in advisory mode during invasive procedures
and pacing, inappropriate therapy never occurred. During
movement artifacts in three patients, the device alarmed on
five occasions but the episode was classified correctly within
2 to 4 s by the AECD. During monitoring, patients had no
restrictions on movement beyond those normally incurred in
their course of treatment. The response time was 14  4 s.
Spontaneous or induced non-sustained and sustained
monomorphic or polymorphic VT as well as VF were always
correctly detected and classified (sensitivity of 100%). In
addition, all those episodes (n  35), which were treated by
the device (invasive procedures, n 12; ward, n  23) were
successfully (100% efficacy) converted to normal rhythms
(Fig. 1) (first shock success 94.3%). Those 23 AECD
interventions in the ward were for VF episodes (n  15),
monomorphic VT (n  6), polymorphic VT (n  1), and
hemodynamically intolerable atrial flutter (n  1). All
AECD shocks during invasive procedures were given be-
cause of hemodynamically not tolerable VT or VF, which
could not be interrupted by pacing or with the ICD that
should be implanted.
Furthermore, during ICD implantation, a detection delay
(mean 6.1 s, range 0 to 8 s) was observed in the recognition
of the induced VF when T-wave shock or 50-Hz current
with the ICD was used for arrhythmia induction. This delay
was caused by saturation of the front end stage of the device.
There were no complications or adverse events.
DISCUSSION
The main findings of this study are that the AECD is safe
and highly effective in monitoring, detecting, and treating
spontaneous rhythms. The use of the device shortens the
response time to CA to a mean of 15 s. Therefore, a
significant improvement in the treatment of in-hospital CA
should be expected with its wide use. Furthermore, extend-
ing the capabilities of monitoring units (intensive care unit,
coronary care unit, and emergency room) to non-monitored
wards is feasible and could lead to allocation of human
resources to critical areas for patients needing closer medical
attention.
Previous studies. Only one clinical study has evaluated this
technology (21). Although some differences exist (e.g.,
sample size, hours of monitoring, definition of episodes,
software version), the present study reaffirms the initial
clinical experience in the U.S. trial with the device (21) in
which the authors reported a sensitivity of 100% and a
specificity of 98.8%. Both studies led to the same conclu-
sions (e.g., the highly effective performance and safety of the
device). The present study shows a shorter response time
(15 s) than that reported by the American investigators
(22 s) as a result of technological (e.g., software) improve-
ment.
Effects of time to shock. Ischemia risk and defibrillation
thresholds increase with arrhythmia duration (4). Therefore,
early intervention (arrhythmia interruption) is mandatory
and clearly improves outcome (1–6,9,13,16,19,22). In ad-
dition, more than two decades of experience with electro-
physiologic testing (including induction of fast VT and VF)
and worldwide testing and implantation of several thousand
ICDs have provided evidence that “early” arrhythmia inter-
ruption has virtually a 100% clinical efficacy without sec-
ondary neurologic damage. These data stress the usefulness
and safety of immediate interruption of even lethal arrhyth-
mias.
In-hospital CA. Sustained VT and VF even in hospital-
ized patients are major causes of morbidity and mortality
(8,13,15,19,20). Although survival to hospital discharge
offers an objective evaluation point and is used in the broad
majority of reports, several patients who survive a CA
present neurologic damage, which is highly dependent on
the response time to CA (1,5,8,9,13,16,17). Therefore, the
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Figure 1. (A) T-wave oversensing may be observed during ventricular pacing as indicated by the markers. (B and C) Recordings of the AECD response to two episodes of spontaneous VF in two different
patients. The first circle indicates the beginning of charge (200 J) of the device; the second circle indicates the full charge of the automatic external cardioverter defibrillator, which was in advisory mode.
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neurologic status should also be considered when reporting
results of resuscitation procedures (13,18).
The absence of in-hospital early defibrillation programs is
evident in the scarcity of data related to deployment of
AECDs in hospitals and its impact on patient outcome
(13,15,20). Continuous ECG monitoring allows identifica-
tion of such arrhythmias, and alarm systems alert nursing
and medical staff. However, a time delay between the
arrhythmic event and human intervention obviously exists
(recognition of the arrhythmia by the ECG monitoring
system; alarming process; reaction of personnel such as
interpretation of rhythm and response to the arrhythmia,
including transport of necessary equipment). Furthermore,
although difficult to accept, this time delay may be pro-
longed in certain circumstances, even in monitoring wards.
In addition, response time intervals for in-hospital resusci-
tation events are often inaccurate and must be corrected
before documented times to defibrillation can be considered
reliable (18).
As stated in major guidelines, early defibrillation is a
high-priority goal in both out-of-hospital and in-hospital
CA (18,23–25). Clearly, the earlier defibrillation occurs, the
better the prognosis (1,2,5,6,10–12,14,16). The capability
to provide early defibrillation within patient-care areas
should be considered as an obligation of the modern
hospital, which is possible with the evaluated technology.
It is well known that several episodes of CA often occur
outside monitored areas. Recently, Herlitz et al. (15) re-
ported that out of 557 patients suffering in-hospital CA,
only 292 patients (53%) were in monitored wards, and from
those only 43.2% of the patients could be discharged alive.
They reported that the median interval between collapse
and first defibrillation was 1 min in monitored wards and 5
min in non-monitored wards. Only 31% of patients from
non-monitored wards could be discharged alive, and with a
cerebral performance inferior to that of survivors of moni-
tored wards. Other authors (20) present similar data show-
ing better in-hospital survival for witnessed arrest (25%)
than for non-witnessed arrest (7%) but, in addition, they
report a disproportionately high incidence of non-witnessed
arrests during the night (12 AM to 6 AM), resulting in a very
poor survival rate (0%).
Future perspectives. This prospective, multicenter Euro-
pean trial suggests that in-hospital CA morbidity and
mortality could be reduced by a safe and highly effective,
new, fully AECD. In addition, the device could save
resources of critical areas (e.g., coronary care unit) for
patients needing closer medical support by extending the
capabilities of traditional monitored wards to other areas of
the hospital with a higher patient/nurse ratio. Examples
include patients admitted with an acute myocardial infarc-
tion (carrying a risk of primary VF), patients waiting for
ICD implantation, or patients waiting for transplantation
who do not present a severe, acute hemodynamic compro-
mise. Furthermore, CA mortality in non-monitored wards
is very high (15,20), reflecting a lack of human resources and
the inadequacy of our risk stratification strategies. Thus,
very rapid intervention with the technology described in this
study could reduce morbidity and mortality associated with
CA (e.g., neurologic damage). These are goals of any
modern hospital and should be a new standard of care.
Study limitations. The study evaluated the response of the
AECD to both spontaneous and induced arrhythmias.
T-wave oversensing during ventricular pacing (rarely) and
an arrhythmia detection delay (mean 6.1 s) after T-wave
shock or using 50 Hz during ICD implantations were
observed independent of the quality of the sensed signal
during the spontaneous rhythm. The device is designed for
the detection and treatment of spontaneous ventricular
tachyarrhythmias. Pacing, T-wave shock, or 50-Hz current
were only used in the study for investigational purposes.
CONCLUSIONS
Early automatic defibrillation of in-hospital CA is now
feasible with a device which is fast (response time 15 s),
safe (no complications occurred), and effective for detecting
and classifying arrhythmias (sensitivity 100%, specificity
97.6%) as well as for treating those events that required
counter-shock therapy (100% efficacy). It is likely that the
use of this device will significantly improve the outcome of
patients with in-hospital CA.
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APPENDIX
The European Powerheart investigators are as follows:
University Hospital de la Sta. Creu i St. Pau (Barcelona,
Spain): Antoni Martı´nez-Rubio, MD, FESC, FACC;
Montserrat Navarra, RN; Roser Genaro, RN; Pelayo Tor-
ner, MD; Jordi Guarinos, MD; Ramo´n Oter, MD; Concha
Alonso, MD; Miquel Santalo´, MD; Salvador Benito, MD;
Hector Litvan, MD; Juan Cinca, MD, FESC. University
Hospital of Mannheim (Mannheim, Germany): Martin Borg-
grefe, MD, FESC; Ayse Bilbal, MD; Constanze Heene,
MD; Susanne Spehl, MD; Christian Wolpert, MD. Au-
gustinum Stiftsklinik (Muenchen, Germany): Michael Block,
MD; Michael Stock, MD. University Hospital of Helsinki
(Helsinki, Finland): Markku Ma¨kija¨rvi, MD, FESC. Uni-
versity Hospital of Rome (Rome, Italy): Francesco Fedele,
MD; Carlo Lavalle, MD. Hospital San Raffaele (Milan,
Italy): Carlo Pappone, MD; Patrizio Mazzone, MD. Uni-
versity Hospital of Muenster (Muenster, Germany): Wilhelm
Haverkamp, MD; Sascha Rolf, MD. University Hospital La
Paz (Madrid, Spain): Jose´ Luis Merino, MD, FESC; Rafael
Peinado, MD; Elena Morala, RN. University Hospital
Virgen del Rocio (Seville, Spain): Gonzalo Baro´n Esquivias,
MD. Cardiac Science Inc. (Irvine, California): Nabil Kanaan,
PhD.
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